Media and Communications

News

Generics

Thursday, December 01, 2011
Teva Announces Tentative Approval of Generic Lipitor®

JERUSALEM, Dec 01, 2011 (BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, the generic version of Pfizer's Lipitor®. Annual sales of Lipitor® were approximately $7.8 billion in the United States as of September 2011, based on IMS sales data. Teva anticipates launching this product at the end of Ranbaxy's 180-day exclusivity period in May 2012. A portion of the profits from Ranbaxy's sales of Ato Read More »

Wednesday, November 30, 2011
Teva Announces Agreement with Ranbaxy Regarding Generic Lipitor(R)

JERUSALEM, Nov 30, 2011 (BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited ("Ranbaxy"), a portion of the profits from Ranbaxy's sales of Atorvastatin Calcium Tablets during Ranbaxy's 180-day first-to-file exclusivity period, will be paid to Teva. Terms of the agreement will not be disclosed.   Atorvastatin Calcium Tablets are the generic version of Pfizer's Lipitor(R) Tablets. Annual sales of Lipitor(R) were approximately $7.8 bill Read More »

Monday, September 26, 2011
Teva Solidifies Japanese Operations with Complete Buyout of Partner's Interest in Teva's Japanese Joint Venture

-- Broader Platform Reinforces Teva's Position in the Fast GrowingJapanese Generics Market -- JERUSALEM, Sep 26, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will acquire the 50% interest formerly held by Kowa Company Ltd. in Teva's Japanese joint venture for a total purchase price of $150 million. With this acquisition, Teva will own 100% of the former joint venture, which will immediately begin to do business as an important and wholly-owned member of the Teva Group. Teva and Kowa announced the establishment of Teva-Kowa Pharma Co., Read More »

Thursday, July 28, 2011
Teva Announces Launch of CamreseTM the Authorized Generic of Seasonique ®

JERUSALEM, Jul 28, 2011 (BUSINESS WIRE) -- Teva Pharmaceuticals USA, the U.S.-based generic arm of Teva Pharmaceuticals announced that it will sell Camrese TM as the Authorized Generic of Seasonique® which is also manufactured by Teva Pharmaceuticals. This product will continue to be manufactured under the brand product's new drug application or NDA at the same facility where it is currently produced. "As both a brand and generic company, we realize that we must remain competitive with other potential generic versions of this product," stated Timothy Crew, head of Teva North Amer Read More »

Tuesday, May 31, 2011
Teva and Pfizer Settle Generic Neurontin® Litigation

Jerusalem, Israel, May 31, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that patent litigation with Pfizer Inc. related to generic versions of Pfizer's Neurontin® (gabapentin) capsules and tablets sold by Teva and its subsidiary IVAX Pharmaceuticals has been dismissed by the United States District Court for the District of New Jersey pursuant to a settlement between the parties, which provides for a full release of Teva and its subsidiaries. The financial terms of the settlement are confidential.About TevaTeva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a lead Read More »

Thursday, May 26, 2011
Teva Announces Approval of Generic Combivir Tablets: Launch Expected in Fourth Quarter 2011

Jerusalem, Israel, May 26, 2011 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the US Food and Drug Administration (FDA) has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of ViiV Healthcare Company's HIV treatment, Combivir Tablets (Lamivudine and Zidovudine). Shipment is expected to commence during the fourth quarter 2011, as per the terms of a settlement agreement between Teva and Glaxo Group Ltd. and ViiV Healthcare.The brand product had annual sales of approximately $315 million in the United States, based Read More »

Wednesday, January 26, 2011
Teva and APP Announce Launch of Generic Gemzar® Pursuant to Agreement

Jerusalem, Israel, January 26, 2011 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar®, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies. Annual sales of Eli Lilly and Company's Gemzar® were approximately $785 million in the United States in 2010, based on IMS sales data.Under the agreement, APP will manufacture Gemcitabine HCI for Injection and will receive a Read More »

Tuesday, January 25, 2011
Teva Receives FDA Action Letter For Generic Lovenox®

Jerusalem, Israel, January 25, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has received correspondence from the U.S. Food and Drug Administration (FDA) regarding the Company's abbreviated new drug application (ANDA) for generic Lovenox® (enoxaparin sodium) injection. The receipt of this action letter, called a Minor Deficiency letter, indicates that the FDA has completed its review of the ANDA including the Company's responses to key questions during the review process. Prior to potential final product approval, the Office of Generic Drugs requires respons Read More »

Tuesday, December 21, 2010
Teva and Takeda Settle Generic ACTOS® and ACTOplus met® Litigation

Jerusalem, Israel, December 21, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to settle patent litigation related to Teva's generic versions of Takeda's ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) for the United States. Takeda has granted Teva a license to market an authorized generic version of ACTOS® in the U.S. beginning on August 17, 2012, or earlier under certain circumstances. Furthermore, Takeda has granted Teva a license to market an authoriz Read More »

Monday, October 18, 2010
Teva Announces Launch of Generic Prevacid® SoluTab in the United States

Jerusalem, October 18, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Takeda's Prevacid® (lansoprazole) SoluTab. Shipment of this product has commenced. Annual sales of the brand product were approximately $453 million in the United States, based on IMS sales data.About TevaTeva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality heal Read More »

​​​